Login Register Cart 0
Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Opinion Article

Non-Pharmaceutical Interventions are Measures to Control Coronavirus Disease-2019 (COVID-19) Transmission in India

Author(s): Ponnuswamy Vijayaraghavan* and Srikrishnan Rajendran Sriramkumar

Volume 2, Issue 3, 2021

Published on: 04 September, 2020

Page: [278 - 283] Pages: 6

DOI: 10.2174/2666796701999200905092833

Price: $65

Abstract

The coronavirus disease 19 (COVID-19) is a pathogenic and transmittable viral disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and this disease emerged in December 2019 in Wuhan, China. It was later spread across the world, including the United States, Great Britain, Brazil, Russia, Germany, Spain, Italy, Iran, Pakistan, India and other countries. The whole genome of SARS-CoV-2 shared some similarity with the SARS virus, hence bat was a suspected source of the spread of this virus in China. However, human to human transfer was reported. In India, more than 300 COVID-19 cases were reported on March 21, 2020, and these numbers were increased as 892551 on July 13, 2020. These numbers of COVID-19 cases were detected from a total of 11806256 samples according to the report given by the Government of India. On July 13, Maharashtra state of India recorded a total of 254427 cases and 10289 deaths were registered. Tamilnadu was another state that screened more number of COVID-19 cases, followed by Maharashtra. On July 6, 114978 COVID-19 cases were reported in Tamilnadu and 1571 deaths were recorded. In Tamilnadu alone, over 3000 COVID-19 cases were reported daily from July first week to the second week and total cases were 142798 on July 13, 2020. Among these cases, 78573 COVID-19 cases were detected in Chennai city alone accounted for about 62% of total COVID-19 cases. It was earlier believed that patients over aged 60 and less than 10 were highly vulnerable to this disease. However, this disease affected all age groups. To prevent COVID-19, no approved antiviral vaccine or drug has yet been discovered. COVID-19 is transmitted through droplets during coughing and sneezing by symptomatic and asymptomatic carriers. Non-pharmaceutical interventions such as washing hands and social distancing are effective measures to control COVID-19 transmission in India. The present study was designed to analyze the control measures of COVID-19 infection and ground reality to control the COVID-19 outbreak.

Keywords: Coronavirus, disease, prevention, control, non-pharmaceutical, challenges.

[1]
Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J Med Virol 2020; 92(4): 401-2.
[http://dx.doi.org/10.1002/jmv.25678] [PMID: 31950516]
[2]
Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020; 382(13): 1199-207.
[http://dx.doi.org/10.1056/NEJMoa2001316] [PMID: 31995857]
[3]
World Health Organization. Coronavirus Disease (COVID-19) Dashboard. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-20192020.
[4]
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061-9.
[http://dx.doi.org/10.1001/jama.2020.1585] [PMID: 32031570]
[5]
Chang D, Lin M, Wei L, et al. Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China. JAMA 2020; 323(11): 1092-3.
[http://dx.doi.org/10.1001/jama.2020.1623] [PMID: 32031568]
[6]
Zhao S, Lin Q, Ran J, et al. Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: a data-driven analysis in the early phase of the outbreak. Int J Infect Dis 2020; 92: 214-7.
[http://dx.doi.org/10.1016/j.ijid.2020.01.050] [PMID: 32007643]
[7]
Yoo JH. The fight against the 2019-nCoV outbreak: an arduous march has just begun. J Korean Med Sci 2020; 35(4)e56
[http://dx.doi.org/10.3346/jkms.2020.35.e56] [PMID: 31997618]
[8]
Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents 2020; 55(3)105924
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105924.]
[9]
Bai Y, Yao L, Wei T, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA 2020; 323(14): 1406-7.
[http://dx.doi.org/10.1001/jama.2020.2565] [PMID: 32083643]
[10]
Nussbaumer‐Streit B, Mayr V, Dobrescu AI, et al. Quarantine alone or in combination with other public health measures to control COVID‐19: a rapid review. Cochrane Database Syst Rev 2020; 2020: 4.
[http://dx.doi.org/10.1002/14651858.CD013574]]
[11]
Du Toit A. Outbreak of a novel coronavirus. Nat Rev Microbiol 2020; 18(3): 123.
[http://dx.doi.org/10.1038/s41579-020-0332-0] [PMID: 31988490]
[12]
Ren LL, Wang YM, Wu ZQ, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl) 2020; 133(9): 1015-24.
[http://dx.doi.org/10.1097/CM9.0000000000000722] [PMID: 32004165]
[13]
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[14]
Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med 2020; 382(13): 1199-207.
[http://dx.doi.org/10.1056/NEJMoa2001316] [PMID: 31995857]
[15]
Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends 2019; 14(1): 69-71.
[http://dx.doi.org/10.5582/bst.2020.01020]]
[16]
Bassetti M, Vena A, Giacobbe DR. The Novel Chinese Coronavirus. The novel Chinese coronavirus (2019-nCoV) infections: challenges for fighting the storm. Eur J Clin Invest 2020; 50(3)e13209
[http://dx.doi.org/10.1111/eci.13209] [PMID: 32003000]
[17]
Weinberger DM, Chen J, Cohen T, et al. Estimation of excess deaths associated with the COVID-19 pandemic in the United States, March to May 2020. JAMA Int Med 2020; 180(10): 1336-44.
[http://dx.doi.org/10.1001/jamainternmed.2020.3391]
[18]
Tiwari S, Kumar S, Guleria K. Outbreak trends of Coronavirus disease–2019 in India: a prediction. Disaster Med Pub Health Prepare 2020; 2020: 1-6.
[19]
World Health Organization. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports2020.
[20]
Sohrabi C, Alsafi Z, O’Neill N, et al. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int J Surg 2020; 76: 71-6.
[http://dx.doi.org/10.1016/j.ijsu.2020.02.034] [PMID: 32112977]
[21]
Zhang Y, Xu Jiuyang, Li. Hui, Cao. Bin. A Novel Coronavirus (COVID-19) outbreak a call for action Beijing, China. Chest 2020; 57(4): e99-101.
[http://dx.doi.org/10.1016/j.chest.2020.02.014]
[22]
Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med 2020; 382(10): 970-1.
[http://dx.doi.org/10.1056/NEJMc2001468] [PMID: 32003551]
[23]
Dashraath P, Jeslyn WJL, Karen LMX, et al. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. Am J Obstet Gyn 2020; 222(6): 521-31.
[http://dx.doi.org/10.1016/j.ajog.2020.03.021]
[24]
Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol 2020; 92(4): 441-7.
[http://dx.doi.org/10.1002/jmv.25689] [PMID: 31994742]
[25]
Guan WJ, Ni ZY, Hu Y, Laing WH, Ou CQ, He JX, et al. Clinical characteristics of 2019 novel coronavirus infection in China. MedRxiv 2019; 2019: 1.
[http://dx.doi.org/10.1101/2020.02.06.20020974.]]
[26]
Chu CM, Cheng VCC, Hung IFN, et al. HKU/UCH SARS Study Group. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004; 59(3): 252-6.
[http://dx.doi.org/10.1136/thorax.2003.012658] [PMID: 14985565]
[27]
Momattin H, Al-Ali AY, Al-Tawfiq JA. A systematic review of therapeutic agents for the treatment of the Middle East respiratory syndrome coronavirus (MERS–CoV). Travel Med Infect Dis 2019; 30: 9-18.
[http://dx.doi.org/10.1016/j.tmaid.2019.06.012] [PMID: 31252170]
[28]
Xu Z, Peng C, Shi Y, et al. Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation. bioRxiv 2020; 2020: 1-20.
[http://dx.doi.org/10.1101/2020.01.27.921627]]
[29]
Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020; 11(1): 222.
[http://dx.doi.org/10.1038/s41467-019-13940-6] [PMID: 31924756]
[30]
Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral Remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio 2018; 2018: 1.
[http://dx.doi.org/0.1128/mBio.00221-18]
[31]
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269-71.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029]
[32]
Holshue ML, DeBolt C, Lindquist S, et al. Washington State 2019-nCoV case investigation team. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020; 382(10): 929-36.
[http://dx.doi.org/10.1056/NEJMoa2001191] [PMID: 32004427]
[33]
Tian X, Li C, Huang A, et al. Potent binding of 2019 novel coronavirus spike pro- tein by a SARS coronavirus-specific human monoclonal antibody. BioRxiv 2020; 9(1): 382-5.
[http://dx.doi.org/10.1080/22221751.2020.1729069] [PMID: 32065055]
[34]
Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 2020; 395(10223): e30-1.
[http://dx.doi.org/10.1016/S0140-6736(20)30304-4] [PMID: 32032529]
[35]
Han Q, Lin Q, Jin S, You L. Coronavirus 2019-nCoV: a brief perspective from the front line. J Infect 2020; 80(4): 373-7.
[http://dx.doi.org/10.1016/j.jinf.2020.02.010] [PMID: 32109444]
[36]
Bootsma MC, Ferguson NM. The effect of public health measures on the 1918 influenza pandemic in U.S. cities. Proc Natl Acad Sci USA 2007; 104(18): 7588-93.
[http://dx.doi.org/10.1073/pnas.0611071104] [PMID: 17416677]
[37]
Xiao J, Shiu EYC, Gao H, et al. Nonpharmaceutical measures for pandemic influenza in nonhealthcare settings-personal protective and environmental measures. Emerg Infect Dis 2020; 26(5): 967-75.
[http://dx.doi.org/10.3201/eid2605.190994] [PMID: 32027586]
[38]
World Health Organization. Situation reports Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/
[39]
Mahase E. COVID-19: schools set to close across UK except for children of health and social care workers. BMJ 2020; 368: m1140.
[http://dx.doi.org/10.1136/bmj.m1140] [PMID: 32193197]
[40]
Fong MW, Gao H, Wong JY, et al. Nonpharmaceutical measures for pandemic influenza in nonhealthcare settings-social distancing measures. Emerg Infect Dis 2020; 26(5): 976-84.
[http://dx.doi.org/10.3201/eid2605.190995] [PMID: 32027585]
[41]
Mahase E. COVID-19: deaths in Mexico triple since reopening began in June. BMJ 2020; 370: m2753.
[http://dx.doi.org/10.1136/bmj.m2753] [PMID: 32646860]
[42]
Adolph C, Amano K, Bang-Jensen B, Fullman N, Wilkerson J. Pandemic politics: timing state-level social distancing responses to COVID-19. MedRxiv 2020; 2020: 8802162.
[http://dx.doi.org/10.1215/03616878-8802162]

Rights & Permissions Print Cite
Article Metrics
9
1
© 2024 Bentham Science Publishers | Privacy Policy